DUP-937 is a new anthrapyrazole intercalator that inhibits DNA synthesis. A phase I trial was conducted in which DUP-937 was given in an intravenous bolus weekly for 3 weeks. Cycles were repeated every 5 weeks. Twenty men and 13 women with median ECOG performance status of 1 completed 74 cycles. The starting dose was 0.55 mg/m2/week and doses were escalated to 16 mg/m2/week. Non-hematological toxicity was generally mild or moderate and consisted mainly of gastro-intestinal effects, fatigue, alopecia and local-reactions. Grade 3 neutropenia was first documented at 7.36 mg/m2 and became more common at higher dose levels. Three of four patients had ≥ grade 3 neutropenia at the 16 mg/m2 dose level. Thrombocytopenia was minimal. The dose-limiting toxicity was neutropenia and the maximum tolerated dose was 16 mg/m2 weekly for 3 weeks. Mean area under the curve (AUC) values increased with dose. Linear pharmacokinetics were observed as total body clearance (CLtb), half-life (t1/2) and volume of distribution (Vss) did not change with increasing doses. One partial remission in a patient with prostate carcinoma was documented.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents with high level, broad spectrum activity against murine tumors. Cancer Res 45:5532–5539, 1985
Showalter HDH, Johnson JL, Hofteizer JM, Turner WR, Werbel LM, Leopold WR, Shillis JL, Jackson RC, Elslager EF: Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. J Med Chem 30(1):212–131, 1987
Showalter HDH, Fry DW, Leopold WR, Lown JW, Plambeck JA, Reszka K: Design, biochemical pharmacology, electrochemistry, and tumor biology of antitumor anthrapyrazoles. Anti-cancer Drug Design 1:73–85, 1986
Fromk P, Novak RF: Effect of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochem Biophys Res Commun 140:797–807, 1986
Pegg DG, Kim SN: Acute intravenous toxicity of CI-937, an anthrapyrazole anti-cancer drug candidate. (Abstract) Toxicologist 6:300, 1986
Paradiso L, Kim S, Pegg D: Toxicity evaluation of CI-937, an anthrapyrazole anticancer agent, in rats. (Abstract) Pharmacologist 28(3):209, 1986
Nordblom GD, Pachla LA, Chang T, Whitfield LR, Showalter HD: Development of radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats. Cancer Res 49:203–216, 1983
Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E, Zee B, Whitfield L: A phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DUP-937) Cancer Res 51:6317–6322, 1991
Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL: A phase I trial and clinical pharmacological evaluation of piroxantrone hydrochloride (Oxantrazole). Cancer Res 50:3905–3909, 1990
Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, MacGuire WP, Ettinger DS, Noe DA, Growchow LB. A phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990
Foster BJ, Graham MA, Newell DR, Gumbrell LA, Calvert AH. A phase I study of the anthrapyrazole CI-941 with pharmacokinetically guided dose escalation. Proc Am Soc Clin Oncol 7:64, 1988
About this article
Cite this article
Bélanger, K., Jolivet, J., Maroun, J. et al. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Invest New Drugs 11, 301–308 (1993). https://doi.org/10.1007/BF00874428
- phase I